Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 17 of 17

Full-Text Articles in Medicine and Health Sciences

Multimorbidity In Patients With Heart Failure From 11 Asian Regions: A Prospective Cohort Study Using The Asian-Hf Registry, Jasper Tromp, Wan Ting Tay, Wouter Ouwekerk, Tiew-Hwa Katherine Teng, Jonathan Yap, Michael R. Macdonald, Kirsten Leineweber, John Mcmurray, Michael R. Zile, Inder S. Anand, Carolyn S. P. Lam Jan 2018

Multimorbidity In Patients With Heart Failure From 11 Asian Regions: A Prospective Cohort Study Using The Asian-Hf Registry, Jasper Tromp, Wan Ting Tay, Wouter Ouwekerk, Tiew-Hwa Katherine Teng, Jonathan Yap, Michael R. Macdonald, Kirsten Leineweber, John Mcmurray, Michael R. Zile, Inder S. Anand, Carolyn S. P. Lam

Faculty of Health Sciences Publications

Background
Comorbidities are common in patients with heart failure (HF) and complicate treatment and outcomes. We identified patterns of multimorbidity in Asian patients with HF and their association with patients’ quality of life (QoL) and health outcomes.
Methods and findings
We used data on 6,480 patients with chronic HF (1,204 with preserved ejection fraction) enrolled between 1 October 2012 and 6 October 2016 in the Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. The ASIAN-HF registry is a prospective cohort study, with patients prospectively enrolled from in- and outpatient clinics from 11 Asian regions (Hong Kong, Taiwan ...


Sex Differences In The Impact Of Body Mass Index On The Risk Of Future Atrial Fibrillation: Insights From The Longitudinal Population-Based Tromso Study, Jocasta Ball, Maja-Lisa Loechen, Tom Wilsgaard, Henrik Schirmer, Laila Arnesdatter Hopstock, Bente Morseth, Ellisiv Bøgeberg Mathiesen, Inger Njolstad, Sweta Tiwari, Ekaterina Sharashova Jan 2018

Sex Differences In The Impact Of Body Mass Index On The Risk Of Future Atrial Fibrillation: Insights From The Longitudinal Population-Based Tromso Study, Jocasta Ball, Maja-Lisa Loechen, Tom Wilsgaard, Henrik Schirmer, Laila Arnesdatter Hopstock, Bente Morseth, Ellisiv Bøgeberg Mathiesen, Inger Njolstad, Sweta Tiwari, Ekaterina Sharashova

Faculty of Health Sciences Publications

Background:
Atrial fibrillation (AF) prevalence is increasing, and body mass index (BMI) is a risk factor for AF. However, sex differences in the impact of BMI on AF risk have not been fully elucidated.
Methods and Results:
Data from the fourth survey (1994–1995) of the Tromsø Study (Norway) were used to investigate the association of single-measurement BMI on future AF risk. To analyze the influence of BMI changes on AF risk, data from individuals who attended the third and fourth study surveys were used. AF diagnosis was derived from record linkage and end point adjudication. Cox regression analysis was ...


Mild Cognitive Impairment Impacts Health Outcomes Of Patients With Atrial Fibrillation Undergoing A Disease Management Intervention, Jocasta Ball, Maja-Lisa Loechen, Melinda Carrington, Joshua Wiley, S. Stewart Jan 2018

Mild Cognitive Impairment Impacts Health Outcomes Of Patients With Atrial Fibrillation Undergoing A Disease Management Intervention, Jocasta Ball, Maja-Lisa Loechen, Melinda Carrington, Joshua Wiley, S. Stewart

Faculty of Health Sciences Publications

Objective: Mild cognitive impairment (MCI) is prevalent in atrial fibrillation (AF) and has the potential to contribute to poor outcomes. We investigated the influence of MCI on survival and rehospitalisation in patients with chronic forms of AF undergoing a home-based, AF-specific disease management intervention (home-based intervention (HBI)) or standard management(SM). Methods The Montreal Cognitive Assessment tool was administered at baseline (a score of < 26/30 indicated MCI) in patients with AF randomised to HBI versus SM. Post hoc analyses of mortality and rehospitalisations during a minimum 24-month follow-up were conducted in the overall cohort and in each study group separately. Results Of 260 patients (mean age 72±11, 47% female), 65% demonstrated MCI on screening (34% in SM; 31% in HBI). Overall, the number of days spent alive and outof- hospital during follow-up (P=0.012) and all-cause rehospitalisation were influenced by MCI during follow-up (OR 3.16 (95% CI 1.46 to 6.84)) but MCI did not influence any outcomes in the SM group. However, survival was negatively influenced by MCI in the HBI group (P=0.036); those with MCI in this group were 5.6 times more likely to die during follow-up (OR 5.57 (95% CI 1.10 to 28.1)). Those with MCI in the HBI group also spent less days alive and out-of-hospital than those with no MCI (P=0.022). MCI was also identified as a significant independent correlate of shortest duration of event-free survival (OR 3.48 (95% CI 1.06 to 11.4)), allcause rehospitalisation (OR 3.30 (95% CI 1.25 to 8.69)) and cardiovascular disease (CVD)-related rehospitalisation (OR 2.35 (95% CI 1.12 to 4.91)) in this group. Conclusions The effectiveness of home-based, disease management for patients with chronic forms of AF is negatively affected by comorbid MCI. The benefit of adjunctive support for patients with MCI on CVD-related health outcomes requires further investigation.


Efficacy And Safety Of Novel Oral Anticoagulants In Patients With Atrial Fibrillation And Heart Failure: A Meta-Analysis, Gianluigi Savarese, Robert P. Giugliano, Giuseppe M.C. Rosano, John Mcmurray, Giulia Magnani, Gerasimos S. Filippatos, Santo Dellegrottaglie, Lars H. Lund, Bruno Trimarco, Pasquale Perrone-Filardi Jan 2016

Efficacy And Safety Of Novel Oral Anticoagulants In Patients With Atrial Fibrillation And Heart Failure: A Meta-Analysis, Gianluigi Savarese, Robert P. Giugliano, Giuseppe M.C. Rosano, John Mcmurray, Giulia Magnani, Gerasimos S. Filippatos, Santo Dellegrottaglie, Lars H. Lund, Bruno Trimarco, Pasquale Perrone-Filardi

Faculty of Health Sciences Publications

Objectives This study investigated the efficacy and safety of novel oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) and heart failure (HF) by a meta-analysis. Background AF is quite prevalent in patients with HF. Methods Four phase III clinical trials comparing NOACs to warfarin in patients with AF were included. Each patient was defined as affected by HF according to the criteria of the trial in which the patient was enrolled. Pre-specified outcomes were the composite of stroke/systemic embolism (SSE); major, intracranial, and any bleeding; and cardiovascular (CV) and all-cause death. Results A total of 55,011 patients ...


Education And Practice Gaps On Atrial Fibrillation And Anticoagulation: A Survey Of Cardiovascular Nurses, Caleb Ferguson, Sally Inglis, Phillip Newton, Sandy Middleton, Peter Macdonald, Patricia Davidson Jan 2016

Education And Practice Gaps On Atrial Fibrillation And Anticoagulation: A Survey Of Cardiovascular Nurses, Caleb Ferguson, Sally Inglis, Phillip Newton, Sandy Middleton, Peter Macdonald, Patricia Davidson

Faculty of Health Sciences Publications

Background Patients’ knowledge of their atrial fibrillation (AF) and anticoagulation therapy are determinants of the efficacy of thromboprophylaxis. Nurses may be well placed to provide counselling and education to patients on all aspects of anticoagulation, including self-management. It is important that nurses are well informed to provide optimal education to patients. Current practice and knowledge of cardiovascular nurses on AF and anticoagulation in the Australian and New Zealand (ANZ) context is not well reported. This study aimed to; 1) Explore the nurse’s role in clinical decision making in anticoagulation in the setting of AF; 2) Describe perceived barriers and ...


Gender And Tachycardia: Independent Modulation Of Platelet Reactivity In Patients With Atrial Fibrillation, Nathan Procter, Jocasta Clare Ball, Doan Ngo, Jeffrey Isenberg, Elaine Hylek, Yuliy Chirkov, Simon Stewart, John Horowitz Jan 2016

Gender And Tachycardia: Independent Modulation Of Platelet Reactivity In Patients With Atrial Fibrillation, Nathan Procter, Jocasta Clare Ball, Doan Ngo, Jeffrey Isenberg, Elaine Hylek, Yuliy Chirkov, Simon Stewart, John Horowitz

Faculty of Health Sciences Publications

Background Female patients with atrial fibrillation (AF) experience increased risk of thromboembolism compared to males, an observation that is reflected by its inclusion in the CHA2DS2VASc score. New onset AF (often associated with tachycardia) also confers upon patients increased thromboembolic risk. The mechanisms underlying this risk are uncertain, but new onset AF is associated with profound impairment of platelet nitric oxide (NO) signalling. Given that cardiovascular responses to catecholamines are gender-dependent, and that the presence of tachycardia in new onset AF may represent a response to catecholaminergic stimulation, we explored the potential impact of gender and tachycardia on platelet aggregation ...


Risk Of Stroke In Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis Of The Controlled Rosuvastatin In Multinational Trial Heart Failure (Corona) And The Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell'insufficienza Cardiaca-Heart Failure (Gissi-Hf) Trials, Azmil H. Abdul-Rahim, Ana Cristina Perez, Rachael L. Fulton, Pardeep Jhund, Roberto Latini, Gianni Tognoni, John Wikstrand, John Kjekshus, Gregory Y. H. Lip, Aldo Pietro Maggioni, Luigi Tavazzi, Kennedy R. Lees, John Mcmurray Jan 2015

Risk Of Stroke In Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis Of The Controlled Rosuvastatin In Multinational Trial Heart Failure (Corona) And The Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell'insufficienza Cardiaca-Heart Failure (Gissi-Hf) Trials, Azmil H. Abdul-Rahim, Ana Cristina Perez, Rachael L. Fulton, Pardeep Jhund, Roberto Latini, Gianni Tognoni, John Wikstrand, John Kjekshus, Gregory Y. H. Lip, Aldo Pietro Maggioni, Luigi Tavazzi, Kennedy R. Lees, John Mcmurray

Faculty of Health Sciences Publications

Our aim was to describe the incidence and predictors of stroke in patients who have heart failure without atrial fibrillation (AF).


Acute Heart Failure And Atrial Fibrillation: Insights From The Acute Study Of Clinical Effectiveness Of Nesiritide In Decompensated Heart Failure (Ascend-Hf) Trial, Seraj Abualnaja, Mohua Podder, Adrian F. Hernandez, John J.V. Mcmurray, Randall C. Starling, Christopher M. O'Connor, Robert M. Califf, Paul W. Armstrong, Justin A. Ezekowitz Jan 2015

Acute Heart Failure And Atrial Fibrillation: Insights From The Acute Study Of Clinical Effectiveness Of Nesiritide In Decompensated Heart Failure (Ascend-Hf) Trial, Seraj Abualnaja, Mohua Podder, Adrian F. Hernandez, John J.V. Mcmurray, Randall C. Starling, Christopher M. O'Connor, Robert M. Califf, Paul W. Armstrong, Justin A. Ezekowitz

Faculty of Health Sciences Publications

Background-—Patients with acute heart failure (AHF) frequently have atrial fibrillation (AF), but how this affects patient-reported outcomes has not been well characterized. Methods and Results-—We examined dyspnea improvement and clinical outcomes in 7007 patients in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial. At baseline, 2677 (38.2%) patients had current or a history of AF and 4330 (61.8%) did not. Patients with a history of AF were older than those without (72 vs. 63 years) and had more comorbidities and a higher median left ventricular ejection fraction (31% vs. 27 ...


History Of Atrial Fibrillation As A Risk Factor In Patients With Heart Failure And Preserved Ejection Fraction, Oludamilola W. Oluleye, Thomas S. Rector, Sithu Win, John Mcmurray, Michael R. Zile, Michel Komajda, Robert Mckelvie, Barry Massie, Peter E. Carson, Inder S. Anand Jan 2014

History Of Atrial Fibrillation As A Risk Factor In Patients With Heart Failure And Preserved Ejection Fraction, Oludamilola W. Oluleye, Thomas S. Rector, Sithu Win, John Mcmurray, Michael R. Zile, Michel Komajda, Robert Mckelvie, Barry Massie, Peter E. Carson, Inder S. Anand

Faculty of Health Sciences Publications

Atrial fibrillation (AFib) is common in heart failure (HF) with preserved ejection fraction (HFpEF). Current AFib stroke risk prediction models include the presence of HF but do not specifically include HFpEF as a risk factor. Whether a history of AFib should be used to identify patients with HFpEF who are at risk has not been established.


High-Sensitivity Troponin I For Risk Assessment In Patients With Atrial Fibrillation: Insights From The Apixaban For Reduction In Stroke And Other Thromboembolic Events In Atrial Fibrillation (Aristotle) Trial, Ziad M. Hijazi, Agneta Siegbahn, Ulrika Andersson, Christopher B. Granger, John H. Alexander, Dan Atar, Bernard J. Gersh, Puneet Mohan, Veli-Pekka Harjola, John Horowitz, Steen Husted, Elaine Hylek, Renato D. Lopes, John Mcmurray, Lars Wallentin Jan 2014

High-Sensitivity Troponin I For Risk Assessment In Patients With Atrial Fibrillation: Insights From The Apixaban For Reduction In Stroke And Other Thromboembolic Events In Atrial Fibrillation (Aristotle) Trial, Ziad M. Hijazi, Agneta Siegbahn, Ulrika Andersson, Christopher B. Granger, John H. Alexander, Dan Atar, Bernard J. Gersh, Puneet Mohan, Veli-Pekka Harjola, John Horowitz, Steen Husted, Elaine Hylek, Renato D. Lopes, John Mcmurray, Lars Wallentin

Faculty of Health Sciences Publications

High-sensitivity troponin-I (hs-TnI) measurement improves risk assessment for cardiovascular events in many clinical settings, but the added value in atrial fibrillation patients has not been described.


High-Sensitivity Troponin T And Risk Stratification In Patients With Atrial Fibrillation During Treatment With Apixaban Or Warfarin, Ziyad Hijazi, Lars Wallentin, Agneta Siegbahn, Ulrika Andersson, John H. Alexander, Dan Atar, Bernard J. Gersh, Michael Hanna, Veli-Pekka Harjola, John D. Horowitz, Steen Husted, Elaine M. Hylek, Renato D. Lopes, John J.V. Mcmurray, Christopher B. Granger Jan 2014

High-Sensitivity Troponin T And Risk Stratification In Patients With Atrial Fibrillation During Treatment With Apixaban Or Warfarin, Ziyad Hijazi, Lars Wallentin, Agneta Siegbahn, Ulrika Andersson, John H. Alexander, Dan Atar, Bernard J. Gersh, Michael Hanna, Veli-Pekka Harjola, John D. Horowitz, Steen Husted, Elaine M. Hylek, Renato D. Lopes, John J.V. Mcmurray, Christopher B. Granger

Faculty of Health Sciences Publications

Objectives The aim of this study was to evaluate the prognostic value of high-sensitivity troponin T (hs-TnT) in addition to clinical risk factors and the CHA2DS2VASc (congestive heart failure, hypertension, 75 years of age and older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, 65 to 74 years of age, female) risk score in patients with atrial fibrillation (AF). Background The level of troponin is a powerful predictor of cardiovascular events and mortality. Methods A total of 14,897 patients with AF were randomized to treatment with apixaban or warfarin in the ARISTOTLE (Apixaban for the Prevention of ...


Beta-Blockers And Outcome In Heart Failure And Atrial Fibrillation: A Meta-Analysis, Michiel Rienstra, Kevin Damman, Bart A. Mulder, Isabelle C. Van Gelder, John J.V. Mcmurray, Dirk J. Van Veldhuisen Jan 2013

Beta-Blockers And Outcome In Heart Failure And Atrial Fibrillation: A Meta-Analysis, Michiel Rienstra, Kevin Damman, Bart A. Mulder, Isabelle C. Van Gelder, John J.V. Mcmurray, Dirk J. Van Veldhuisen

Faculty of Health Sciences Publications

Objectives The purpose of this study was to analyze the effect of beta blockade on outcome in patients with heart failure (HF) and atrial fibrillation (AF). Background Beta-blockers are widely used in patients with HF and AF. Recommendation in current HF guidelines, however, is based on populations in which the most patients had sinus rhythm. Whether beta-blockers are as useful in AF is uncertain. Methods Studies were included that investigated the effect of placebo-controlled, randomized beta-blocker therapy in patients with AF at baseline and HF with reduced systolic left ventricular ejection fraction (LVEF) <40%. Results We identified 4 studies, which enrolled 8,680 patients with HF, and 1,677 of them had AF (19%; mean 68 years of age; 30% women); there were 842 patients treated with beta-blocker, and 835 with placebo. In AF patients, beta-blockade did not reduce mortality (odds ratio [OR]: 0.86 [95% confidence interval (CI): 0.66 to 1.13]; p = 0.28), while in sinus rhythm patients, there was a significant reduction (OR: 0.63 [95% CI: 0.54 to 0.73]; p < 0.0001). Interaction analysis showed significant interaction of the effects of beta-blocker therapy in AF versus that in sinus rhythm (p = 0.048). By meta-regression analysis, we did not find confounding by all relevant covariates. Beta-blocker therapy was not associated with a reduction in HF hospitalizations in AF (OR: 1.11 [95% CI: 0.85 to 1.47]; p = 0.44), in contrast to sinus rhythm (OR: 0.58 [95% CI: 0.49 to 0.68]; p < 0.0001). There was a significant interaction of the effects of beta-blocker therapy in AF versus that in sinus rhythm (p < 0.001). Conclusions Our findings suggest that the effect of beta-blockers on outcome in HF patients with reduced systolic LVEF who have AF is less than in those who have sinus rhythm.


Left Ventricular Systolic Dysfunction, Heart Failure, And The Risk Of Stroke And Systemic Embolism In Patients With Atrial Fibrillation : Insights From The Aristotle Trial, John Mcmurray, Justin A. Ezekowitz, Basil S. Lewis, Bernard J. Gersh, Sean Van Diepen, John Amerena, Jozef Bartunek, Patrick Commerford, Byung Hee Oh, Veli-Pekka Harjola, Sana M. Al-Khatib, Michael Hanna, John H. Alexander, Renato D. Lopes, Daniel M. Wojdyla, Lars Wallentin, Christopher B. Granger Jan 2013

Left Ventricular Systolic Dysfunction, Heart Failure, And The Risk Of Stroke And Systemic Embolism In Patients With Atrial Fibrillation : Insights From The Aristotle Trial, John Mcmurray, Justin A. Ezekowitz, Basil S. Lewis, Bernard J. Gersh, Sean Van Diepen, John Amerena, Jozef Bartunek, Patrick Commerford, Byung Hee Oh, Veli-Pekka Harjola, Sana M. Al-Khatib, Michael Hanna, John H. Alexander, Renato D. Lopes, Daniel M. Wojdyla, Lars Wallentin, Christopher B. Granger

Faculty of Health Sciences Publications

We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARISTOTLE), as well as the effect of apixaban versus warfarin.


Efficacy And Safety Of Apixaban Compared With Warfarin At Different Levels Of Predicted International Normalized Ratio Control For Stroke Prevention In Atrial Fibrillation, Lars Wallentin, Renato D. Lopes, Michael Hanna, Laine Thomas, Anne Hellkamp, Sunil Nepal, Elaine Hylek, Sana M. Al-Khatib, John H. Alexander, Marco Alings, John Amerena, Jack Ansell, Philip Aylward, Jozef Bartunek, Patrick Commerford, Raffaele De Caterina, Çetin Erol, Veli-Pekka Harjola, Claes Held, John Horowitz, Kurt Huber, Steen Husted, Matyas Keltai, Fernando Lanas, Liu Lisheng, John Mcmurray, Byung Hee Oh, Mårten Rosenqvist, Witold Ruzyllo, Philippe Gabriel Steg, Dragos Vinereanu, Denis Xavier, Christopher B. Granger Jan 2013

Efficacy And Safety Of Apixaban Compared With Warfarin At Different Levels Of Predicted International Normalized Ratio Control For Stroke Prevention In Atrial Fibrillation, Lars Wallentin, Renato D. Lopes, Michael Hanna, Laine Thomas, Anne Hellkamp, Sunil Nepal, Elaine Hylek, Sana M. Al-Khatib, John H. Alexander, Marco Alings, John Amerena, Jack Ansell, Philip Aylward, Jozef Bartunek, Patrick Commerford, Raffaele De Caterina, Çetin Erol, Veli-Pekka Harjola, Claes Held, John Horowitz, Kurt Huber, Steen Husted, Matyas Keltai, Fernando Lanas, Liu Lisheng, John Mcmurray, Byung Hee Oh, Mårten Rosenqvist, Witold Ruzyllo, Philippe Gabriel Steg, Dragos Vinereanu, Denis Xavier, Christopher B. Granger

Faculty of Health Sciences Publications

In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effects in relation to 2 predictions of time in therapeutic range (TTR).


N-Terminal Pro-B-Type Natriuretic Peptide For Risk Assessment In Patients With Atrial Fibrillation: Insights From The Aristotle Trial (Apixaban For The Prevention Of Stroke In Subjects With Atrial Fibrillation), Ziyad Hijazi, Lars Wallentin, Agneta Siegbahn, Ulrika Andersson, Christina Christersson, Justin Ezekowitz, Bernard J. Gersh, Michael Hanna, Stefan Hohnloser, John Horowitz, Kurt Huber, Elaine M. Hylek, Renato D. Lopes, John J.V. Mcmurray, Christopher B. Granger Jan 2013

N-Terminal Pro-B-Type Natriuretic Peptide For Risk Assessment In Patients With Atrial Fibrillation: Insights From The Aristotle Trial (Apixaban For The Prevention Of Stroke In Subjects With Atrial Fibrillation), Ziyad Hijazi, Lars Wallentin, Agneta Siegbahn, Ulrika Andersson, Christina Christersson, Justin Ezekowitz, Bernard J. Gersh, Michael Hanna, Stefan Hohnloser, John Horowitz, Kurt Huber, Elaine M. Hylek, Renato D. Lopes, John J.V. Mcmurray, Christopher B. Granger

Faculty of Health Sciences Publications

Objectives This study sought to assess the prognostic value of N-terminal pro–B-type natriuretic peptide (NT-proBNP) in patients with atrial fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trial, and the treatment effect of apixaban according to NT-proBNP levels. Background Natriuretic peptides are associated with mortality and cardiovascular events in several cardiac diseases. Methods In the ARISTOTLE trial, 18,201 patients with AF were randomized to apixaban or warfarin. Plasma samples at randomization were available from 14,892 patients. The association between NT-proBNP concentrations and clinical outcomes was evaluated using Cox ...


Association Of Heart Rate And Outcomes In A Broad Spectrum Of Patients With Chronic Heart Failure: Results From The Charm (Candesartan In Heart Failure: Assessment Of Reduction In Mortality And Morbidity) Program, Davide Castagno, Hicham Skali, Madoka Takeuchi, Karl Sweberg, Salim Yusuf, Christopher B. Granger, Eric L. Michelson, Marc A. Pfeffer, John J.V. Mcmurray, Scott D. Solomon Jan 2012

Association Of Heart Rate And Outcomes In A Broad Spectrum Of Patients With Chronic Heart Failure: Results From The Charm (Candesartan In Heart Failure: Assessment Of Reduction In Mortality And Morbidity) Program, Davide Castagno, Hicham Skali, Madoka Takeuchi, Karl Sweberg, Salim Yusuf, Christopher B. Granger, Eric L. Michelson, Marc A. Pfeffer, John J.V. Mcmurray, Scott D. Solomon

Faculty of Health Sciences Publications

No abstract provided.


Eplerenone And Atrial Fibrillation In Mild Systolic Heart Failure: Results From The Emphasis-Hf (Eplerenone In Mild Patients Hospitalization And Survival Study In Heart Failure) Study, Karl Sweberg, Faiez Zannad, John J.V. Mcmurray, Henry Krum, Dirk J. Van Veldhuisen, Harry Shi, John Vincent, Bertram Pitt Jan 2012

Eplerenone And Atrial Fibrillation In Mild Systolic Heart Failure: Results From The Emphasis-Hf (Eplerenone In Mild Patients Hospitalization And Survival Study In Heart Failure) Study, Karl Sweberg, Faiez Zannad, John J.V. Mcmurray, Henry Krum, Dirk J. Van Veldhuisen, Harry Shi, John Vincent, Bertram Pitt

Faculty of Health Sciences Publications

No abstract provided.